Show simple item record

Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.

dc.contributor.author Guan, Xiaoxiang
dc.contributor.author Yin, Ming
dc.contributor.author Wei, Qingyi
dc.contributor.author Zhao, Hui
dc.contributor.author Liu, Zhensheng
dc.contributor.author Wang, Li-E
dc.contributor.author Yuan, Xianglin
dc.contributor.author O'Reilly, Michael S
dc.contributor.author Komaki, Ritsuko
dc.contributor.author Liao, Zhongxing
dc.date.accessioned 2019-02-01T15:24:57Z
dc.date.available 2019-02-01T15:24:57Z
dc.date.issued 2010-08-16
dc.identifier 1471-2407-10-431
dc.identifier.issn 1471-2407
dc.identifier.issn 1471-2407
dc.identifier.uri https://hdl.handle.net/10161/18014
dc.description.abstract Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis involving in carcinogenesis, including lung cancer. We hypothesized that VEGF polymorphisms may affect survival outcomes among locally advanced non-small cell lung cancer (LA-NSCLC) patients.We genotyped three potentially functional VEGF variants [-460 T > C (rs833061), -634 G > C (rs2010963), and +936 C > T (rs3025039)] and estimated haplotypes in 124 Caucasian patients with LA-NSCLC treated with definitive radiotherapy. We used Kaplan-Meier log-rank tests, and Cox proportional hazard models to evaluate the association between VEGF variants and overall survival (OS).Gender, Karnofsky's performance scores (KPS) and clinical stage seemed to influence the OS. The variant C genotypes were independently associated with significantly improved OS (CT+CC vs. TT: adjusted hazard ratio [HR] = 0.58; 95% confidence interval [CI] = 0.37-0.92, P = 0.022), compared with the VEGF -460 TT genotype.Our study suggests that VEGF -460 C genotypes may be associated with a better survival of LA-NSCLC patients after chemoradiotherapy. Large studies are needed to confirm our findings.
dc.language eng
dc.publisher Springer Science and Business Media LLC
dc.relation.ispartof BMC cancer
dc.relation.isversionof 10.1186/1471-2407-10-431
dc.subject Humans
dc.subject Adenocarcinoma
dc.subject Carcinoma, Large Cell
dc.subject Carcinoma, Non-Small-Cell Lung
dc.subject Carcinoma, Squamous Cell
dc.subject Lung Neoplasms
dc.subject Vascular Endothelial Growth Factor A
dc.subject Antineoplastic Combined Chemotherapy Protocols
dc.subject Neoplasm Staging
dc.subject Treatment Outcome
dc.subject Combined Modality Therapy
dc.subject Radiotherapy Dosage
dc.subject Survival Rate
dc.subject Follow-Up Studies
dc.subject Genotype
dc.subject Haplotypes
dc.subject Polymorphism, Single Nucleotide
dc.subject Adult
dc.subject Aged
dc.subject Aged, 80 and over
dc.subject Middle Aged
dc.subject Female
dc.subject Male
dc.title Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.
dc.type Journal article
duke.contributor.id Wei, Qingyi|0632334
duke.contributor.id Liu, Zhensheng|0633329
dc.date.updated 2019-02-01T15:24:55Z
pubs.begin-page 431
pubs.issue 1
pubs.organisational-group Staff
pubs.organisational-group Duke
pubs.organisational-group School of Medicine
pubs.organisational-group Duke Cancer Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Population Health Sciences
pubs.organisational-group Basic Science Departments
pubs.organisational-group Medicine, Medical Oncology
pubs.organisational-group Medicine
pubs.organisational-group Clinical Science Departments
pubs.publication-status Published
pubs.volume 10
duke.contributor.orcid Wei, Qingyi|0000-0002-3845-9445|0000-0003-4115-4439


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record